New drug lorigerlimab takes on Platinum-Resistant ovarian cancer
NCT ID NCT06730347
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing a drug called lorigerlimab in about 80 people with advanced ovarian or clear cell gynecologic cancers that have stopped responding to platinum chemotherapy. Lorigerlimab is a bispecific antibody designed to activate the immune system against tumors. Researchers will measure how many participants' tumors shrink and monitor side effects closely.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Lorigerlimab (a bispecific antibody that targets PD-1 and CTLA-4 to help the immune system fight cancer)
- What this could lead to
- If successful, this could point toward a new treatment option for people with hard-to-treat ovarian and clear cell gynecologic cancers.
- What could go wrong
- This is a small, early-phase trial (80 people) with no control group, so results may not apply broadly. The drug can cause immune-related side effects, and many experimental cancer drugs fail to show enough benefit.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLEAR CELL ADENOCARCINOMA OF CERVIX are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Gangnam Severance Hospital
RECRUITINGSeoul, 06273, South Korea
-
Korea University Guro Hospital
RECRUITINGSeoul, 08308, South Korea
-
McGill University
RECRUITINGMontreal, Quebec, H4A3J1, Canada
-
National Cancer Center
RECRUITINGGoyang-si, Gyeonggi-do, 410-763, South Korea
-
Ochsner MD Anderson Cancer Center
RECRUITINGNew Orleans, Louisiana, 70115, United States
-
Princess Margaret Cancer Center
RECRUITINGToronto, Ontario, M5G 2M9, Canada
-
START Midwest
RECRUITINGGrand Rapids, Michigan, 49546, United States
-
START San Antonio
RECRUITINGSan Antonio, Texas, 78229, United States
-
Samsung Medical Center
RECRUITINGSeoul, 135-710, South Korea
-
Seoul National University Hospital
RECRUITINGSeoul, 110-74, South Korea
-
Seoul National University Hospital Bundang Hospital
RECRUITINGSeongnam-si, Gyeonnggi-Do, 463-707, South Korea
-
The University of Texas MD Anderson Cancer Center, Gynecologic Oncology Center
RECRUITINGHouston, Texas, 77030, United States
-
UCLA
RECRUITINGLos Angeles, California, 90095, United States
-
West Penn Allegheny Health
RECRUITINGPittsburgh, Pennsylvania, 15224, United States
-
Wisconsin Institute Medical Research- UW Cancer Connect
RECRUITINGMadison, Wisconsin, 53705, United States
-
Yonsei University Health System Severance Hospital
RECRUITINGSeoul, 03722, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- What raises endometrial cancer risk in black women? a study digs in
- Can immunotherapy plus hormones spare the womb in early endometrial cancer?
- Can a new drug tackle Hard-to-Treat gynecologic cancers?
- Can a pill restore the Body's tumor suppressor to fight multiple cancers?
- Could gentle yoga and breathing ease Cancer's lingering toll?